Not a Lexis+ subscriber? Try it out for free.


Mealey's PI/Product Liability - FDA: Withdraw Belviq Weight- Loss Drug Due To Increased Cancer In Study Subjects

SILVER SPRING, Md. - The Food and Drug Administration on Feb. 13 said it has asked Eisai Co. Ltd. to voluntarily withdraw the company's Belviq and Belviq XR prescription weight loss drug from the U.S. market because the company's safety clinical trial showed an increased occurrence of cancer, including pancreatic, colorectal and lung cancer.
Find full version on lexis Advance®